London, 12 January 2015 –Increased prevalence of cancer has resulted in the unprecedented growth of the Global Cancer Biomarkers Market, which is expected to post a CAGR of 18.26 percent from 2014-2019, says research firm TechNavio.
The number of cancer-related death is growing globally, topping 8 million in 2012. Lifestyle factors like a poor diet, sedentary habits, smoking and alcohol consumption have all been tied to cancer, and contribute significantly to the increased rates of the disease.
The latest report by TechNavio emphasizes the growing popularity of companion diagnostics as a major growth driver in the Global Cancer Biomarkers Market. A companion diagnostic test is a biomarker assay that enables physicians to make better treatment decisions for their patients.
“Pharmaceutical companies and diagnostic manufacturers are working together to develop companion diagnostic tests,” says Faisal Ghaus, Vice President of TechNavio.
The Food & Drug Administration has recently approved a companion diagnostic genetic test to select patients with metastatic colorectal cancer for treatment with the drug Vectibix, which helps detect seven mutations in the KRAS gene in colorectal tumor tissue.
TechNavio currently has more than 3000 market research reports on a huge range of topics, including:
https://www.technavio.com/%3Cp%3E%3Cstrong%3EAbout%20TechNavio%3C/strong%…
